SKYE · XBRL financial data

Skye Bioscience financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (SKYE's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
General and administrative	2,236	2,495*	4,206	4,327	4,639	4,554*	4,562	3,906	3,907	3,426*	4,739	3,869
Total operating expenses	24,706	4,086*	6,152	8,406	4,969	10,666*	11,760	18,244	13,265	14,896*	12,674	11,061
Operating income (loss)	(24,706)	(4,086)*	(6,152)	(8,406)	(4,969)	(10,666)*	(11,760)	(18,244)	(13,265)	(14,896)*	(12,674)	(11,061)
Interest income	17	50*	427	961	908	732*	619	533	418	274*	170	103
Interest expense	271	430*	437	450	(91)	(47)*	1	0	0	0*	2	3
Other income (expense)	0	0*	(1)	(0)	(1)	0*	41	0	0	(1)*	(2)	0
Income tax expense (benefit)	0	0*	2	8	0	0*	2	3	0	0*	0	3
Net income (loss)	(24,946)	(4,420)*	(5,020)	(7,903)	(3,898)	(9,746)*	(11,103)	(17,625)	(12,755)	(14,442)*	(12,509)	(10,787)
Earnings per share, basic USD per share	(3.17)	—	(0.18)	(0.20)	(0.10)	(0.24)*	(0.28)	(0.44)	(0.32)	(0.36)*	(0.32)	(0.27)
Earnings per share, diluted USD per share	(3.17)	—	(0.18)	(0.20)	(0.10)	(0.24)*	(0.28)	(0.44)	(0.32)	(0.36)*	(0.32)	(0.27)
Weighted average shares, basic thousands of shares	7,881	—	28,000	38,669	38,819	40,389*	39,652	39,659	39,666	39,673*	39,681	39,694
Weighted average shares, diluted thousands of shares	7,881	—	28,000	38,669	38,819	40,389*	39,652	39,659	39,666	39,673*	39,681	39,694

Fiscal quarters (SKYE's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	5,126	1,256	83,343	74,121	67,413	68,416	46,421	23,838	18,441	5,882	8,149	8,068
Short-term investments	—	—	—	—	—	0	12,803	24,747	16,871	19,855	8,960	1,996
Total current assets	15,286	11,651	94,570	87,004	79,808	70,827	63,028	50,583	39,925	27,094	18,567	10,959
Property and equipment, net	55	43	36	46	1,517	1,433	1,304	1,169	1,034	899	756	33
Right-of-use asset	255	238	221	203	185	450	407	355	312	267	58	34
Total assets	15,604	11,940	94,835	87,262	81,536	72,764	64,793	52,161	41,324	28,314	19,417	11,034
Accounts payable	1,631	1,156	1,095	1,079	780	569	1,714	3,223	2,825	2,033	3,937	4,278
Total current liabilities	13,719	13,901	15,801	14,323	5,624	4,339	5,319	8,312	8,368	8,205	10,405	11,531
Lease liability, non-current	191	171	151	130	108	273	223	172	120	84	0	0
Total liabilities	13,909	14,072	15,952	14,452	5,732	4,612	5,543	8,484	8,488	8,289	10,405	11,531
Accumulated deficit	(99,963)	(104,383)	(109,402)	(117,305)	(121,203)	(130,950)	(142,053)	(159,678)	(172,433)	(186,874)	(199,384)	(210,170)
Total stockholders' equity	1,695	(2,132)	78,883	72,809	75,803	68,152	59,250	43,677	32,836	20,024	9,012	(497)
Total liabilities and equity	15,604	11,940	94,835	87,262	81,536	72,764	64,793	52,161	41,324	28,314	19,417	11,034
Common shares outstanding (cover page) thousands of shares	12,339	28,063	28,068	30,338	30,338	30,975	30,984	30,988	32,057	33,379	35,144	35,421

Fiscal quarters (SKYE's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(24,946)	(4,420)*	(5,020)	(7,903)	(3,898)	(9,746)*	(11,103)	(17,625)	(12,755)	(14,442)*	(12,509)	(10,787)
Stock-based compensation	160*	593*	2,478	1,828*	1,922*	2,089*	2,202	2,033*	1,914*	1,619*	1,497	1,271*
Depreciation and amortization	13	86*	28	30*	48	229*	177	187*	179*	180*	173	158*
Net cash from operating activities	(4,055)*	(3,845)*	(4,708)	(7,094)*	(5,263)*	(8,173)*	(9,185)	(10,746)*	(13,364)*	(9,766)*	(8,558)	(7,122)*
Purchases of property and equipment	4*	7*	3	32*	1,518*	50*	6	0*	0*	0*	0	0*
Net cash from investing activities	1,073*	(7)*	1,142	(32)*	(1,446)*	90*	(12,809)	(11,855)*	7,967*	(2,804)*	10,896	7,142*
Proceeds from issuing common stock	—	(6,761)*	—	—	—	(83,557)*	—	—	—	—	—	—
Net cash from financing activities	16,635*	(23)*	85,653	(2,096)*	0*	6*	0	18*	0*	11*	(72)	(101)*
Net change in cash	13,653*	(3,874)*	82,086	(9,222)*	(6,708)*	(8,077)*	(21,994)	(22,583)*	(5,397)*	(12,559)*	2,267	(81)*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Skye Bioscience	8,068	not reported	(7,122)*	35.4M	1.4 quarters	Q2 FY26 10-QJun 30, 2026
Agenus	18,738	34,518	(31,199)*	45.0M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
Vistagen Therapeutics	16,991	not reported	(14,707)	44.4M	2.2 quarters	Q1 FY27 10-QJun 30, 2026
Kodiak Sciences	125,903	not reported	(46,238)*	62.8M	2.7 quarters	Q2 FY26 10-QJun 30, 2026
Voyager Therapeutics	35,769	3,165	(25,842)*	61.6M	4.5 quarters	Q2 FY26 10-QJun 30, 2026
Eledon Pharmaceuticals	6,803	not reported	(22,677)*	81.3M	3.9 quarters	Q2 FY26 10-QJun 30, 2026
Puma Biotechnology	36,537	56,502	1,624*	51.6M	—	Q2 FY26 10-QJun 30, 2026
Alector	59,915	3,320	(34,217)*	111.7M	5.1 quarters	Q2 FY26 10-QJun 30, 2026
Neurogene	112,485	not reported	(23,761)*	20.0M	9.5 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.